VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

NCT03327727 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

Invasive Aspergillosis
Invasive Pulmonary Aspergillosis

Interventions

DRUG: Investigational Agent: VL-2397
DRUG: Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B

Sponsor

Vical